Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients (Q43624652)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A T van Oosterom

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

H T Mouridsen

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

O S Nielsen

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

P Dombernowsky

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

K Krzemieniecki

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

I Judson

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

L Svancarova

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

D Spooner

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

C Hermans

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

M Van Glabbeke

10

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

J Verweij

11

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

EORTC Soft Tissue and Bone Sarcoma Group

12

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

publication date

1 December 2002

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

38

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

2397-2406

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality control of validity of data collected in clinical trials. EORTC Study Group on Data Management (SGDM).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900491-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(02)00491-4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43624652&oldid=2101957375"